Thu, Jan 29, 2015, 6:16 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Venaxis, Inc. Message Board

fivecrackers 33 posts  |  Last Activity: Jan 26, 2015 7:07 PM Member since: Dec 21, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • fivecrackers by fivecrackers Jan 26, 2015 7:07 PM Flag

    So I have been holding MNKD's insulin supplier (AMPH) stock and am happy with the performance. Much much more upside for both!

    Sentiment: Strong Buy

  • Reply to

    e mail notice

    by underscore_hater Jan 24, 2015 2:31 AM
    fivecrackers fivecrackers Jan 24, 2015 12:43 PM Flag

    The big money needs to cover... so after approximately 17 days based on the current volume... is when positive press about the launch can occur... or when the share price is at about $11 per share.

  • Reply to

    Search Al Mann and he said April

    by fedupp100 Jan 24, 2015 10:21 AM
    fivecrackers fivecrackers Jan 24, 2015 12:39 PM Flag

    Al will be having lauch at Vons in March or April apparently.

  • Reply to

    50.00 per share....

    by bmcgoo_03 Jan 23, 2015 10:40 AM
    fivecrackers fivecrackers Jan 24, 2015 12:17 PM Flag

    $682 per share capturing 10% of the 400 million diabetics.
    Big Bang!!! :)

  • fivecrackers fivecrackers Jan 23, 2015 10:58 PM Flag

    pump- pump - pump. This equity needs no fluffy air pumping from small time investors. It needs only to be manipulated as it is, so that those with volumes of dollars can increase their share of the pie.

  • Go to WebMD and search for: What Type of Insulin Is Best for My Diabetes?
    Click on the first result.
    There is plenty of exposure here for newly diagnosed diabetics...as well as the 371 million who already have it.

    Sentiment: Strong Buy

  • Reply to

    SA Doctor

    by dclegal531 Jan 4, 2015 12:41 PM
    fivecrackers fivecrackers Jan 4, 2015 1:53 PM Flag

    Your Circular Reference (Doctors are not going to prescribe this until they see how it goes with the people who will be currently using it.") voids your entire post and the article you are attempting to support. " So, "I think" that Doctors have an opportunity to prescribe this rapid acting inhalable instead of inferior (statistically significant) Novolog/Humalog injectables. And to your point, when Doctors do prescribe this, it will spread like a wild fire. since they can read all about the trials that have proven people can and will use it.

    Sentiment: Strong Buy

  • fivecrackers by fivecrackers Jan 4, 2015 1:17 PM Flag

    12/17/2014 Express Scripts, Inc. (Anthem)
    Medication: Afrezza (insulin human) inhalation
    Quantity Limit: 4 units – 6 cartridges per day 8 units – 9 cartridges per day
    OVERRIDE(S)
    Prior Authorization of Benefits
    APPROVAL DURATION
    1 year
    APPROVAL CRITERIA
    Requests for Afrezza (insulin human) may be approved if the following criteria are met (either I, II, or III) AND (IV, V, and VI):
    I. Individual has been on the Afrezza (insulin human) in the previous 180 days; OR
    II. Individual has had a previous trial of one preferred rapid‐acting insulin (Novolog or
    Humalog) in the previous 180 days.; OR
    III. Individual is requesting Afrezza and is unable or unwilling to administer injectable insulin.
    AND
    IV. Individual is 18 years of age or older; AND
    V. Individual has a diagnosis of diabetes mellitus and one of the following:
    a. For type 1 diabetes, individual will be using concurrently with long‐acting insulin;
    OR
    b. For type 2 diabetes, individual has inadequate control, intolerance, or
    contraindication to at least 2 oral anti‐diabetic medications;
    VI. Individual has had a physical examination including detailed medical history to identify
    potential lung disease.
    Afrezza (insulin human) may not be approved for the following:
    I. Individuals with a diagnosis of chronic lung disease, such as asthma or chronic obstructive pulmonary disease; OR
    II. Individuals who smoke cigarettes or who recently (within 6 months) quit smoking; OR
    III. As a treatment for diabetic ketoacidosis.
    Note: Afrezza (insulin human) has a black box warning for the risk of acute bronchospasm in individuals with chronic lung disease. Afrezza is contraindicated in individuals with chronic lung disease such as asthma or COPD. Acute bronchospasm has been observed in these individuals. Before initiating therapy, a detailed medical history, physical exam, and spirometry (FEV1) should be performed to identify potential lung disease.
    PAGE 1 of 1 12/17/2014 Express Scripts, Inc.

  • Reply to

    Is it just me or

    by lars1551 Jan 4, 2015 10:25 AM
    fivecrackers fivecrackers Jan 4, 2015 11:12 AM Flag

    The reasons for shorting this down are probably many. But, the biggest reason is accumulation for humongous gains ahead. Afrezza is a game changer in treating diabetes mellitus and threatens market share capture with the likes of Novolog and Humalog.

    Sentiment: Buy

  • fivecrackers fivecrackers Jan 4, 2015 10:55 AM Flag

    This is from Anthem dated 12/17/2014

    Medication

    Quantity Limit

    Afrezza (insulin human) inhalation
    4 units – 6 cartridges per day 8 units – 9 cartridges per day
    OVERRIDE(S)
    Prior Authorization of Benefits
    APPROVAL DURATION
    1 year
    APPROVAL CRITERIA
    Requests for Afrezza (insulin human) may be approved if the following criteria are met (either I, II, or III) AND (IV, V, and VI):
    I. Individual has been on the Afrezza (insulin human) in the previous 180 days; OR
    II. Individual has had a previous trial of one preferred rapid‐acting insulin (Novolog or
    Humalog) in the previous 180 days.; OR
    III. Individual is requesting Afrezza and is unable or unwilling to administer injectable insulin.
    AND
    IV. Individual is 18 years of age or older; AND
    V. Individual has a diagnosis of diabetes mellitus and one of the following:
    a. For type 1 diabetes, individual will be using concurrently with long‐acting insulin;
    OR
    b. For type 2 diabetes, individual has inadequate control, intolerance, or
    contraindication to at least 2 oral anti‐diabetic medications;
    VI. Individual has had a physical examination including detailed medical history to identify
    potential lung disease.
    Afrezza (insulin human) may not be approved for the following:
    I. Individuals with a diagnosis of chronic lung disease, such as asthma or chronic obstructive pulmonary disease; OR
    II. Individuals who smoke cigarettes or who recently (within 6 months) quit smoking; OR
    III. As a treatment for diabetic ketoacidosis.
    Note: Afrezza (insulin human) has a black box warning for the risk of acute bronchospasm in individuals with chronic lung disease. Afrezza is contraindicated in individuals with chronic lung disease such as asthma or COPD. Acute bronchospasm has been observed in these individuals. Before initiating therapy, a detailed medical history, physical exam, and spirometry (FEV1) should be performed to identify potential lung disease.
    PAGE 1 of 1 12/17/2014
    Express Scripts, Inc. is a separate company that provides pharmacy services and pharmacy benefit management services on behalf of health plan members.
    AND

  • fivecrackers fivecrackers Jan 2, 2015 1:27 PM Flag

    I like your post, but shorts are making a killing... their resolve is far from being a 'Throw in the Towel' situation. They are and have been controlling this stock. Lets see if the short interest continues to drop. They (Hedgies) planned it well and clearly have the cash to do more damage until positive fundamentals arrive. I am long and buy during the bear attacks.

    Sentiment: Buy

  • Reply to

    Silence & Stock Price = Big Announcement Coming

    by kevinmik Dec 29, 2014 11:03 AM
    fivecrackers fivecrackers Dec 29, 2014 11:08 AM Flag

    Agreed...and I would add that it is the Market Makers (along with Mannkind & Sanofi) controlling the price. It is the MM's job to do so.

  • fivecrackers fivecrackers Dec 24, 2014 5:19 PM Flag

    good news! A slow and steady cover to $8 based on statistics and market condition

  • Reply to

    Bottom - I am calling it

    by fivecrackers Oct 9, 2014 12:41 PM
    fivecrackers fivecrackers Dec 24, 2014 9:46 AM Flag

    Colton.. you have now infected the Appy board? Why be here..? when you are so popular and loved on the MNKD board?

  • fivecrackers by fivecrackers Dec 24, 2014 9:40 AM Flag

    The count should have been reported by the mid of the month. My sites don't show the record. Can anyone else find it?

  • Reply to

    The Short Cover Continues

    by fivecrackers Dec 23, 2014 9:59 AM
    fivecrackers fivecrackers Dec 23, 2014 10:20 AM Flag

    I know this the same way you don't know it.

  • fivecrackers by fivecrackers Dec 23, 2014 9:59 AM Flag

    RBC $13 per share valuation is conservative folks.

    Sentiment: Strong Buy

  • Reply to

    Why would they buy only in AH?

    by kevinvests Dec 22, 2014 11:04 AM
    fivecrackers fivecrackers Dec 22, 2014 11:54 AM Flag

    They covered short from $10. I too would take $4.40 profit x 2 million short shares. Now they (the big money manipulating this) are orchestrating a beautiful buy short covering with more selling of short shares.

  • Reply to

    Gap up Tommorow

    by fivecrackers Dec 19, 2014 6:07 PM
    fivecrackers fivecrackers Dec 19, 2014 6:13 PM Flag

    Red Wine

APPY
0.55-1.49(-73.14%)Jan 29 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.